---
layout: default
title: Fulvestrant
parent: 僅模型預測 (L5)
nav_order: 454
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the provided Evidence Pack, here is the evaluation report.

---

# Fulvestrant: From HR+/HER2- Advanced Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

> Fulvestrant is a Selective Estrogen Receptor Degrader (SERD) whose established clinical use — as reflected throughout this Evidence Pack's supporting trial data — is in hormone receptor-positive (HR+), HER2-negative advanced/metastatic breast cancer.
> The TxGNN model's top-ranked prediction proposes potential efficacy for **HIV infectious disease**, but this direction is currently supported by **0 clinical trials** and only **1 publication**, and that single publication concerns a different retrovirus (HTLV-1, not HIV) entirely unrelated to the predicted indication.
> Evidence strength for this specific prediction is minimal and the internal rationale flags it as a likely knowledge-graph statistical artifact rather than a genuine pharmacological signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hormone receptor-positive (HR+), HER2-negative advanced/metastatic breast cancer (inferred from cited clinical trial context in this pack; not formally recorded as a Singapore-approved indication) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed, source-verified mechanism of action (MOA) data for Fulvestrant is currently a data gap in this evidence pack. However, based on information embedded elsewhere in this pack (the repurposing rationale for other candidate indications explicitly identifies Fulvestrant as an estrogen receptor antagonist/degrader), Fulvestrant's known pharmacology is that of a SERD: it binds and degrades the estrogen receptor, blocking estrogen-driven signaling. This mechanism underlies its established role in HR+/HER2- breast cancer, a role corroborated by the large volume of breast-cancer trials (e.g., MONARCH 2, VERITAC-2, and numerous CDK4/6-inhibitor combination studies) that appear throughout this same evidence pack under other predicted indications.

HIV infection, by contrast, is driven by retroviral entry, reverse transcription, and immune-cell depletion pathways that have no established interaction with estrogen receptor signaling. There is no known shared target, pathway, or pharmacological class linking anti-estrogen therapy to antiretroviral activity.

Consistent with this, the mechanistic assessment already included in the data explicitly states that Fulvestrant has no known antiviral or HIV-pathway-related mechanism, and that the single associated publication actually concerns HTLV-1-associated myelopathy (HAM) — a distinct retrovirus and a distinct neuroinflammatory disease, not HIV. This mismatch suggests the high TxGNN score likely reflects a statistical association from shared graph nodes (e.g., immune/viral-disease clustering) rather than a real biological signal. On current evidence, the mechanism does **not** meaningfully support this predicted indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Cross-omics Cohort Analysis (preprint) | Research Square | Multi-cohort (epi)genomic/systems-biology analysis of HTLV-1-associated myelopathy (HAM), a neuroinflammatory disease caused by HTLV-1 (a different retrovirus from HIV). The study notes current HAM treatment is symptomatic and borrowed from HIV/multiple sclerosis strategies — it does **not** study Fulvestrant or HIV directly, and is only tangentially connected via retrovirus/immune-disease terminology. |

*Note: This article was published on Research Square, a preprint server, and has not undergone peer review at time of indexing. It does not constitute direct evidence for a Fulvestrant–HIV link.*

---

## Singapore Market Information

Fulvestrant is not currently registered or marketed in Singapore — there are 0 authorizations on file, and market status is recorded as "Not Marketed."

---

## Cytotoxicity

Fulvestrant is an antineoplastic agent (hormonal/endocrine therapy for breast cancer), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted/hormonal therapy — Selective Estrogen Receptor Degrader (SERD), not a conventional cytotoxic chemotherapeutic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (HIV infectious disease) has zero supporting clinical trials and only one loosely related, non-peer-reviewed publication that concerns a different retrovirus and disease entirely; the internal mechanistic assessment itself flags this as a likely spurious knowledge-graph association rather than a real pharmacological signal. Combined with the drug's non-marketed status in Singapore and a Blocking data gap on safety labeling, there is currently no basis to advance this candidate beyond initial screening (S0).

**To proceed, the following is needed:**
- HSA/manufacturer package insert with warnings, precautions, and contraindications (Blocking gap — required before any safety pre-assessment)
- Confirmed mechanism of action via DrugBank or primary literature (currently a data gap)
- A dedicated literature/mechanism search specifically on Fulvestrant and HIV/antiretroviral pathways, since the current single reference does not address this link
- Manual review of the TxGNN disease-node mapping for "HIV infectious disease" to rule out graph-embedding artifacts, given the absence of any supporting trial or on-topic literature
- If pursued further, consider instead evaluating rank 6 (rheumatoid arthritis), which has directional/mechanistic literature (L4, though with conflicting estrogen-signaling direction) rather than rank 1, which has essentially no support
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

